Brokerages Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Target Price at $173.14

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has received a consensus recommendation of “Moderate Buy” from the fourteen analysts that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $173.14.

A number of research firms have commented on JAZZ. Piper Sandler dropped their price target on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a research report on Thursday, August 1st. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Royal Bank of Canada lifted their price target on Jazz Pharmaceuticals from $174.00 to $175.00 and gave the company an “outperform” rating in a research report on Friday, October 4th. UBS Group dropped their price objective on Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 2nd. Finally, Morgan Stanley decreased their target price on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research note on Friday, July 12th.

Insider Buying and Selling

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now owns 14,531 shares in the company, valued at $1,573,707.30. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of JAZZ. Rise Advisors LLC grew its position in Jazz Pharmaceuticals by 2,255.6% during the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 203 shares in the last quarter. Versant Capital Management Inc boosted its stake in shares of Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 269 shares during the period. Itau Unibanco Holding S.A. purchased a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at $29,000. EverSource Wealth Advisors LLC increased its stake in shares of Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 97 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 116 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 0.0 %

NASDAQ:JAZZ opened at $113.10 on Friday. The firm has a market capitalization of $7.13 billion, a PE ratio of 23.32, a price-to-earnings-growth ratio of 1.34 and a beta of 0.57. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $134.48. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. The stock has a 50 day moving average of $111.01 and a 200-day moving average of $109.64.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 EPS for the quarter, beating the consensus estimate of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Analysts predict that Jazz Pharmaceuticals will post 16.03 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.